---
layout: minimal-medicine
title: Rituximab
---

# Rituximab
### Generic Name
Rituximab

### Usage

Rituximab is a monoclonal antibody medication primarily used to treat various types of B-cell non-Hodgkin's lymphoma (NHL), including previously untreated and relapsed/refractory forms.  It's also approved for chronic lymphocytic leukemia (CLL),  in combination with methotrexate for rheumatoid arthritis (RA) in adults who haven't responded well to TNF antagonist therapies, and for granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), both in adults and children (≥2 years).  Additionally, it treats moderate-to-severe pemphigus vulgaris in adults.  While primarily used for these conditions, Rituximab also sees off-label use in a range of other autoimmune and lymphoproliferative disorders, often in combination with other therapies.  These off-label uses require careful consideration and monitoring by a healthcare professional.

### Dosage

Rituximab dosage varies significantly depending on the condition being treated and the patient's characteristics.  It's always administered intravenously (IV) and should only be given by a healthcare professional experienced in administering such medications.  Dosages are often expressed as mg/m² (milligrams per square meter of body surface area), requiring calculation based on the patient's height and weight.  

**Specific dosage regimens for different conditions are extensive and complex.  The information provided in the source material is detailed and includes numerous variations based on the specific disease, treatment phase (induction vs. maintenance), and combinations with other drugs.  Directly consulting the prescribing information or a healthcare provider is crucial for accurate dosage determination.**  

Examples of dosage ranges (from the provided data) include:

* **NHL:** 375 mg/m² on day 1 of each chemotherapy cycle (various numbers of cycles)
* **CLL:** 375 mg/m² to 500 mg/m² depending on the cycle and combination therapy
* **RA:** 1000 mg on days 1 and 15 (with methotrexate), followed by courses every 16-24 weeks.
* **GPA/MPA (Adults):** 375 mg/m² weekly for 4 doses (induction), then varying maintenance doses.
* **Pemphigus Vulgaris:** 1000 mg every 2 weeks for 2 doses (followed by maintenance doses).

**Children's dosages are also highly variable and require precise calculation by a pediatrician or oncologist familiar with Rituximab's use in children.**

### Side Effects

Common side effects of Rituximab can include:

* Infusion reactions (ranging from mild to severe, potentially fatal)
* Infections (increased risk due to immunosuppression)
* Nausea and vomiting
* Headache
* Fatigue
* Dizziness
* Rash
* Low white blood cell count (leukopenia)
* Low platelet count (thrombocytopenia)


Less common but serious side effects may include:

* Progressive multifocal leukoencephalopathy (PML) – a rare and potentially fatal brain infection.
* Hepatitis B reactivation – can lead to liver failure.
* Severe mucocutaneous reactions – serious skin reactions.
* Renal toxicity – kidney damage.
* Cardiac arrhythmias – irregular heartbeats.
* Tumor lysis syndrome – a complication of rapid cancer cell breakdown.


**Any new or worsening symptoms should be reported to a doctor immediately.**

### How it Works

Rituximab is a targeted therapy that specifically binds to the CD20 protein found on the surface of B-lymphocytes (a type of white blood cell). By attaching to CD20, Rituximab triggers several mechanisms that lead to the destruction of these B cells.  These mechanisms include complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC).  In the context of diseases like lymphoma and leukemia, this reduces the number of cancerous B cells. In autoimmune diseases like RA, it helps to modulate the overactive immune response driven by these cells.

### Precautions

* **Hypersensitivity:** Individuals with known allergies to Rituximab or its components should avoid its use.
* **Infections:** Rituximab weakens the immune system, increasing the risk of infections. Patients should be closely monitored for signs of infection.  Active infections should be treated before initiating Rituximab therapy.
* **Immunizations:** Live vaccines are not recommended during treatment or for a period afterward.
* **Pregnancy and Breastfeeding:**  Rituximab can harm a developing fetus.  Women of childbearing age should use effective contraception during treatment and for a significant period afterward.  Breastfeeding is not recommended during and for an extended period after treatment.
* **Renal and Hepatic Impairment:**  Patients with impaired kidney or liver function may require dosage adjustments or close monitoring.
* **Drug Interactions:** Rituximab can interact with other medications, particularly those that also affect the immune system or kidneys.  This should be discussed thoroughly with a doctor before starting treatment.
* **Cardiac Issues:** Rituximab can cause cardiac problems, including arrhythmias, so appropriate cardiac monitoring is necessary, especially in high-risk patients.
* **Tumor Lysis Syndrome:**  This is a potential complication, particularly in patients with a high tumor burden.  Preventive measures may be taken.


### FAQs

* **How is Rituximab stored?**  Consult the specific product labeling for exact storage recommendations, as it varies by formulation.
* **How long does Rituximab treatment typically last?** Treatment duration depends on the specific disease, response to therapy, and the treatment protocol, varying from a few weeks to months or even longer for maintenance therapy.
* **Are there any specific foods to avoid during Rituximab therapy?**  There are typically no specific dietary restrictions, but maintaining a healthy and balanced diet is advisable.
* **Can Rituximab be used with other medications?**  It's frequently used in combination with other treatments, such as chemotherapy or other immunomodulatory drugs. The specific combinations are dependent upon the disease being treated and the treatment protocol. The prescribing information and a healthcare provider must be consulted to ensure no contraindications are present.
* **What should I do if I miss a dose of Rituximab?**  Rituximab is administered intravenously by a healthcare professional. Missed doses need to be addressed and adjusted by a doctor in conjunction with the established treatment protocol.
* **When should I contact my doctor about Rituximab treatment?**  Contact your doctor immediately if you experience any concerning side effects, such as severe infusion reactions, signs of infection, or unusual symptoms.


**Disclaimer:** This information is for general knowledge and does not constitute medical advice.  Always consult with a healthcare professional for diagnosis, treatment, and any questions regarding Rituximab or any other medication. The details provided here are based on the source material; however, specific formulations and protocols can differ.  Always refer to the most current prescribing information for the specific Rituximab product being used.
